Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gambling | 138 | 2024 | 146 | 43.850 |
Why?
|
Trichotillomania | 81 | 2024 | 88 | 37.140 |
Why?
|
Obsessive-Compulsive Disorder | 92 | 2023 | 157 | 28.920 |
Why?
|
Disruptive, Impulse Control, and Conduct Disorders | 108 | 2023 | 276 | 23.820 |
Why?
|
Impulsive Behavior | 86 | 2024 | 281 | 23.410 |
Why?
|
Compulsive Behavior | 59 | 2023 | 83 | 19.260 |
Why?
|
Behavior, Addictive | 56 | 2024 | 130 | 18.530 |
Why?
|
Self-Injurious Behavior | 30 | 2023 | 105 | 12.820 |
Why?
|
Students | 23 | 2022 | 147 | 9.440 |
Why?
|
Adult | 313 | 2024 | 25649 | 9.000 |
Why?
|
Young Adult | 163 | 2024 | 5977 | 8.820 |
Why?
|
Comorbidity | 89 | 2023 | 943 | 8.480 |
Why?
|
Substance-Related Disorders | 42 | 2023 | 394 | 8.430 |
Why?
|
Cognition | 34 | 2023 | 570 | 7.500 |
Why?
|
Mental Disorders | 37 | 2019 | 371 | 6.900 |
Why?
|
Male | 308 | 2024 | 40973 | 6.660 |
Why?
|
Adolescent | 147 | 2023 | 8982 | 6.580 |
Why?
|
Female | 320 | 2024 | 44537 | 6.540 |
Why?
|
Psychiatric Status Rating Scales | 64 | 2022 | 487 | 6.450 |
Why?
|
Humans | 448 | 2024 | 86653 | 6.380 |
Why?
|
Depressive Disorder, Major | 17 | 2023 | 158 | 6.010 |
Why?
|
Sexual Behavior | 23 | 2023 | 302 | 5.900 |
Why?
|
Anxiety Disorders | 30 | 2024 | 148 | 5.900 |
Why?
|
Skin | 28 | 2022 | 554 | 5.800 |
Why?
|
Naltrexone | 29 | 2021 | 135 | 5.720 |
Why?
|
Internet | 23 | 2023 | 312 | 5.460 |
Why?
|
Narcotic Antagonists | 29 | 2021 | 154 | 5.200 |
Why?
|
Quality of Life | 39 | 2023 | 1585 | 5.150 |
Why?
|
Cognition Disorders | 18 | 2019 | 236 | 5.090 |
Why?
|
Neuropsychological Tests | 45 | 2023 | 502 | 5.060 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 41 | 2022 | 216 | 4.990 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 11 | 2022 | 183 | 4.820 |
Why?
|
Executive Function | 11 | 2020 | 86 | 4.680 |
Why?
|
Personality | 14 | 2023 | 134 | 4.570 |
Why?
|
Compulsive Personality Disorder | 14 | 2023 | 16 | 4.390 |
Why?
|
Severity of Illness Index | 60 | 2019 | 1801 | 4.080 |
Why?
|
Middle Aged | 170 | 2024 | 25028 | 4.000 |
Why?
|
Decision Making | 23 | 2020 | 642 | 3.970 |
Why?
|
Personality Disorders | 17 | 2024 | 146 | 3.960 |
Why?
|
Surveys and Questionnaires | 59 | 2023 | 2501 | 3.790 |
Why?
|
Universities | 21 | 2022 | 135 | 3.760 |
Why?
|
Depression | 18 | 2020 | 473 | 3.540 |
Why?
|
Acetylcysteine | 9 | 2022 | 69 | 3.340 |
Why?
|
Cognitive Dysfunction | 8 | 2020 | 132 | 3.270 |
Why?
|
Risk-Taking | 10 | 2020 | 148 | 2.920 |
Why?
|
Alcoholism | 14 | 2023 | 172 | 2.920 |
Why?
|
Body Dysmorphic Disorders | 9 | 2019 | 12 | 2.890 |
Why?
|
Anxiety | 15 | 2024 | 287 | 2.860 |
Why?
|
Psychotropic Drugs | 10 | 2020 | 75 | 2.790 |
Why?
|
Prevalence | 34 | 2022 | 1239 | 2.640 |
Why?
|
Double-Blind Method | 39 | 2024 | 1823 | 2.540 |
Why?
|
Catechol O-Methyltransferase | 5 | 2022 | 68 | 2.440 |
Why?
|
Cerebral Cortex | 8 | 2021 | 584 | 2.430 |
Why?
|
Memantine | 6 | 2023 | 10 | 2.350 |
Why?
|
Silymarin | 3 | 2024 | 3 | 2.200 |
Why?
|
Theft | 6 | 2017 | 12 | 2.200 |
Why?
|
Mental Health | 11 | 2021 | 162 | 2.180 |
Why?
|
Reward | 14 | 2023 | 181 | 2.120 |
Why?
|
Alcohol-Related Disorders | 5 | 2020 | 17 | 2.050 |
Why?
|
Prescription Drug Misuse | 3 | 2020 | 13 | 2.040 |
Why?
|
Brain | 23 | 2022 | 2216 | 2.000 |
Why?
|
Aged | 71 | 2023 | 18415 | 1.970 |
Why?
|
Memory, Short-Term | 10 | 2020 | 220 | 1.930 |
Why?
|
Interview, Psychological | 10 | 2018 | 69 | 1.930 |
Why?
|
Alcohol Drinking | 8 | 2019 | 267 | 1.930 |
Why?
|
Treatment Outcome | 52 | 2024 | 7993 | 1.850 |
Why?
|
Central Nervous System Stimulants | 5 | 2018 | 216 | 1.840 |
Why?
|
Firesetting Behavior | 5 | 2018 | 5 | 1.800 |
Why?
|
Magnetic Resonance Imaging | 20 | 2022 | 3362 | 1.780 |
Why?
|
Antidepressive Agents | 6 | 2019 | 106 | 1.750 |
Why?
|
Somatoform Disorders | 8 | 2006 | 29 | 1.730 |
Why?
|
Frontal Lobe | 8 | 2015 | 130 | 1.720 |
Why?
|
Binge-Eating Disorder | 4 | 2021 | 77 | 1.720 |
Why?
|
Obsessive Behavior | 4 | 2021 | 8 | 1.710 |
Why?
|
Dronabinol | 3 | 2022 | 53 | 1.690 |
Why?
|
Psychotherapy | 9 | 2021 | 74 | 1.690 |
Why?
|
Sex Factors | 23 | 2020 | 1054 | 1.680 |
Why?
|
International Classification of Diseases | 4 | 2020 | 69 | 1.640 |
Why?
|
Antipsychotic Agents | 6 | 2020 | 123 | 1.610 |
Why?
|
Depressive Disorder | 11 | 2016 | 218 | 1.600 |
Why?
|
Implosive Therapy | 5 | 2022 | 7 | 1.570 |
Why?
|
Tobacco Use Disorder | 5 | 2018 | 108 | 1.550 |
Why?
|
Age of Onset | 17 | 2020 | 310 | 1.530 |
Why?
|
Deep Brain Stimulation | 4 | 2016 | 54 | 1.510 |
Why?
|
Family | 5 | 2020 | 311 | 1.470 |
Why?
|
Biomedical Research | 6 | 2018 | 376 | 1.470 |
Why?
|
Amphetamine-Related Disorders | 3 | 2021 | 27 | 1.460 |
Why?
|
Sexual and Gender Minorities | 2 | 2023 | 192 | 1.450 |
Why?
|
Placebo Effect | 3 | 2021 | 31 | 1.440 |
Why?
|
Corpus Striatum | 5 | 2019 | 86 | 1.440 |
Why?
|
Obesity | 7 | 2016 | 964 | 1.440 |
Why?
|
Self Report | 15 | 2023 | 288 | 1.410 |
Why?
|
Cross-Sectional Studies | 22 | 2023 | 1621 | 1.390 |
Why?
|
Methamphetamine | 3 | 2021 | 82 | 1.360 |
Why?
|
Desensitization, Psychologic | 4 | 2014 | 4 | 1.350 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 4 | 2016 | 87 | 1.340 |
Why?
|
Antisocial Personality Disorder | 5 | 2017 | 91 | 1.330 |
Why?
|
Psychometrics | 20 | 2023 | 327 | 1.310 |
Why?
|
United States | 31 | 2023 | 6674 | 1.290 |
Why?
|
Attention | 7 | 2023 | 388 | 1.270 |
Why?
|
Borderline Personality Disorder | 3 | 2023 | 33 | 1.250 |
Why?
|
Reaction Time | 9 | 2018 | 309 | 1.230 |
Why?
|
Minnesota | 13 | 2017 | 46 | 1.220 |
Why?
|
Criminals | 2 | 2017 | 33 | 1.210 |
Why?
|
Autistic Disorder | 3 | 2023 | 147 | 1.200 |
Why?
|
Choice Behavior | 7 | 2016 | 160 | 1.160 |
Why?
|
Erotica | 2 | 2018 | 4 | 1.160 |
Why?
|
Homosexuality | 2 | 2020 | 9 | 1.150 |
Why?
|
Sexuality | 2 | 2019 | 40 | 1.130 |
Why?
|
Patient Acceptance of Health Care | 5 | 2018 | 238 | 1.110 |
Why?
|
Exhibitionism | 2 | 2021 | 3 | 1.100 |
Why?
|
Body Image | 5 | 2015 | 76 | 1.100 |
Why?
|
Emotions | 6 | 2023 | 341 | 1.090 |
Why?
|
Case-Control Studies | 12 | 2016 | 1806 | 1.070 |
Why?
|
Homosexuality, Female | 2 | 2023 | 15 | 1.060 |
Why?
|
Caffeine | 2 | 2017 | 81 | 1.060 |
Why?
|
Phenelzine | 2 | 2023 | 2 | 1.040 |
Why?
|
Self Concept | 5 | 2019 | 133 | 1.040 |
Why?
|
Personality Inventory | 12 | 2021 | 108 | 1.040 |
Why?
|
Nail Biting | 5 | 2017 | 5 | 1.020 |
Why?
|
Overweight | 2 | 2016 | 118 | 1.020 |
Why?
|
Analysis of Variance | 11 | 2017 | 912 | 1.010 |
Why?
|
Psychological Tests | 5 | 2021 | 91 | 1.000 |
Why?
|
Sexual Dysfunctions, Psychological | 3 | 2022 | 32 | 0.990 |
Why?
|
Smoking | 6 | 2016 | 609 | 0.980 |
Why?
|
Nitrophenols | 3 | 2013 | 11 | 0.970 |
Why?
|
Quality-Adjusted Life Years | 2 | 2015 | 138 | 0.970 |
Why?
|
Benzophenones | 3 | 2013 | 11 | 0.970 |
Why?
|
Drug Resistance | 4 | 2021 | 256 | 0.960 |
Why?
|
Video Games | 3 | 2020 | 11 | 0.960 |
Why?
|
Age Factors | 15 | 2018 | 1851 | 0.950 |
Why?
|
Cost-Benefit Analysis | 2 | 2018 | 454 | 0.940 |
Why?
|
Problem Behavior | 3 | 2020 | 9 | 0.940 |
Why?
|
Longitudinal Studies | 11 | 2022 | 1019 | 0.930 |
Why?
|
Excitatory Amino Acid Antagonists | 3 | 2013 | 78 | 0.930 |
Why?
|
Clinical Trials as Topic | 8 | 2022 | 1169 | 0.910 |
Why?
|
Stereotypic Movement Disorder | 3 | 2014 | 5 | 0.900 |
Why?
|
Personality Assessment | 9 | 2012 | 98 | 0.900 |
Why?
|
Suicide | 3 | 2014 | 139 | 0.880 |
Why?
|
Pilot Projects | 13 | 2015 | 839 | 0.880 |
Why?
|
Statistics as Topic | 6 | 2016 | 238 | 0.870 |
Why?
|
Adolescent Behavior | 4 | 2011 | 106 | 0.860 |
Why?
|
Transcranial Magnetic Stimulation | 2 | 2020 | 21 | 0.850 |
Why?
|
South Africa | 11 | 2023 | 60 | 0.850 |
Why?
|
Models, Neurological | 2 | 2015 | 405 | 0.850 |
Why?
|
Motivation | 10 | 2022 | 287 | 0.850 |
Why?
|
Follow-Up Studies | 18 | 2019 | 3640 | 0.840 |
Why?
|
Dopamine Agents | 2 | 2020 | 29 | 0.830 |
Why?
|
Models, Psychological | 4 | 2019 | 157 | 0.830 |
Why?
|
Cost of Illness | 2 | 2020 | 150 | 0.830 |
Why?
|
Cold Temperature | 3 | 2019 | 157 | 0.820 |
Why?
|
Liability, Legal | 1 | 2022 | 32 | 0.820 |
Why?
|
Methylphenidate | 2 | 2018 | 10 | 0.810 |
Why?
|
Behavioral Symptoms | 1 | 2021 | 15 | 0.810 |
Why?
|
Craving | 1 | 2021 | 21 | 0.800 |
Why?
|
Dose-Response Relationship, Drug | 14 | 2019 | 1961 | 0.800 |
Why?
|
Evidence-Based Practice | 2 | 2020 | 45 | 0.800 |
Why?
|
Stress, Psychological | 4 | 2016 | 313 | 0.800 |
Why?
|
Temperament | 3 | 2023 | 26 | 0.790 |
Why?
|
Crisis Intervention | 1 | 2021 | 7 | 0.780 |
Why?
|
Disease Progression | 5 | 2019 | 1531 | 0.770 |
Why?
|
Reproducibility of Results | 19 | 2023 | 2705 | 0.770 |
Why?
|
Risk Factors | 16 | 2023 | 5417 | 0.760 |
Why?
|
Minority Groups | 4 | 2023 | 137 | 0.750 |
Why?
|
Anticonvulsants | 1 | 2021 | 126 | 0.750 |
Why?
|
Bisexuality | 3 | 2023 | 32 | 0.750 |
Why?
|
Ownership | 1 | 2020 | 26 | 0.740 |
Why?
|
Midwestern United States | 5 | 2019 | 76 | 0.740 |
Why?
|
Child | 17 | 2023 | 6928 | 0.740 |
Why?
|
Gyrus Cinguli | 3 | 2020 | 45 | 0.730 |
Why?
|
Self-Control | 2 | 2016 | 10 | 0.730 |
Why?
|
Cocaine-Related Disorders | 1 | 2020 | 34 | 0.730 |
Why?
|
Neuroimaging | 2 | 2018 | 113 | 0.720 |
Why?
|
Ketamine | 1 | 2020 | 24 | 0.720 |
Why?
|
Crime | 3 | 2009 | 36 | 0.710 |
Why?
|
Firearms | 1 | 2020 | 49 | 0.700 |
Why?
|
Academic Performance | 1 | 2019 | 6 | 0.700 |
Why?
|
Suicide, Attempted | 5 | 2023 | 129 | 0.700 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 199 | 0.700 |
Why?
|
Academic Success | 1 | 2019 | 11 | 0.700 |
Why?
|
Pain Perception | 1 | 2019 | 18 | 0.700 |
Why?
|
Deception | 1 | 2019 | 20 | 0.700 |
Why?
|
Suicidal Ideation | 4 | 2023 | 67 | 0.690 |
Why?
|
Cross-Cultural Comparison | 5 | 2017 | 34 | 0.690 |
Why?
|
Smartphone | 1 | 2019 | 36 | 0.680 |
Why?
|
Hypnotics and Sedatives | 1 | 2020 | 125 | 0.680 |
Why?
|
Amphetamines | 1 | 2018 | 18 | 0.670 |
Why?
|
Diffusion Tensor Imaging | 4 | 2021 | 67 | 0.660 |
Why?
|
Dopamine Antagonists | 2 | 2018 | 35 | 0.660 |
Why?
|
Triazines | 2 | 2010 | 53 | 0.660 |
Why?
|
Functional Neuroimaging | 1 | 2018 | 32 | 0.660 |
Why?
|
Piperazines | 1 | 2020 | 272 | 0.660 |
Why?
|
Saliva | 2 | 2018 | 122 | 0.660 |
Why?
|
Vaping | 1 | 2019 | 29 | 0.660 |
Why?
|
Phobia, Social | 1 | 2018 | 2 | 0.650 |
Why?
|
Social Behavior Disorders | 2 | 2016 | 19 | 0.640 |
Why?
|
Judgment | 2 | 2020 | 64 | 0.640 |
Why?
|
Independent Living | 1 | 2018 | 18 | 0.640 |
Why?
|
Pain Threshold | 2 | 2016 | 58 | 0.640 |
Why?
|
Electronic Nicotine Delivery Systems | 1 | 2019 | 50 | 0.630 |
Why?
|
Alcohol Deterrents | 1 | 2017 | 2 | 0.630 |
Why?
|
Benzazepines | 2 | 2018 | 89 | 0.630 |
Why?
|
Sleep | 2 | 2020 | 444 | 0.630 |
Why?
|
Disulfiram | 1 | 2017 | 8 | 0.630 |
Why?
|
Progesterone | 1 | 2018 | 110 | 0.630 |
Why?
|
Dietary Sucrose | 1 | 2017 | 13 | 0.620 |
Why?
|
Jurisprudence | 1 | 2017 | 25 | 0.620 |
Why?
|
Soft Tissue Injuries | 1 | 2017 | 12 | 0.620 |
Why?
|
Machine Learning | 2 | 2018 | 232 | 0.620 |
Why?
|
Behavior Therapy | 6 | 2021 | 75 | 0.620 |
Why?
|
Psychotherapy, Brief | 1 | 2017 | 10 | 0.620 |
Why?
|
Antioxidants | 1 | 2019 | 223 | 0.620 |
Why?
|
Mental Competency | 1 | 2017 | 49 | 0.610 |
Why?
|
Vilazodone Hydrochloride | 1 | 2017 | 1 | 0.610 |
Why?
|
Analgesics, Opioid | 2 | 2019 | 413 | 0.610 |
Why?
|
Paroxetine | 6 | 2009 | 26 | 0.600 |
Why?
|
Anorexia Nervosa | 3 | 2022 | 141 | 0.600 |
Why?
|
Inositol | 1 | 2017 | 15 | 0.600 |
Why?
|
Sleep Deprivation | 1 | 2018 | 137 | 0.600 |
Why?
|
Drugs, Investigational | 2 | 2015 | 37 | 0.600 |
Why?
|
Estradiol | 1 | 2018 | 252 | 0.600 |
Why?
|
Neural Pathways | 3 | 2016 | 308 | 0.600 |
Why?
|
Vitamin B Complex | 1 | 2017 | 21 | 0.590 |
Why?
|
Veterans | 1 | 2017 | 72 | 0.590 |
Why?
|
Paraphilic Disorders | 2 | 2021 | 2 | 0.580 |
Why?
|
Bipolar Disorder | 6 | 2012 | 377 | 0.580 |
Why?
|
Dietary Fats | 1 | 2017 | 135 | 0.580 |
Why?
|
Drug Administration Schedule | 9 | 2016 | 916 | 0.580 |
Why?
|
Cycloserine | 1 | 2016 | 5 | 0.580 |
Why?
|
Combined Modality Therapy | 7 | 2015 | 1686 | 0.580 |
Why?
|
Evidence-Based Medicine | 2 | 2018 | 429 | 0.580 |
Why?
|
Symptom Assessment | 1 | 2017 | 65 | 0.580 |
Why?
|
United Kingdom | 9 | 2023 | 164 | 0.570 |
Why?
|
Testosterone | 1 | 2018 | 271 | 0.570 |
Why?
|
Brain Infarction | 1 | 2016 | 22 | 0.570 |
Why?
|
Socioeconomic Factors | 9 | 2015 | 567 | 0.560 |
Why?
|
Research Personnel | 1 | 2016 | 67 | 0.550 |
Why?
|
Nucleus Accumbens | 5 | 2017 | 113 | 0.550 |
Why?
|
Habits | 5 | 2018 | 15 | 0.540 |
Why?
|
Corpus Callosum | 1 | 2016 | 56 | 0.540 |
Why?
|
Diagnosis, Differential | 8 | 2017 | 1565 | 0.540 |
Why?
|
Policy Making | 4 | 2021 | 62 | 0.540 |
Why?
|
Wounds and Injuries | 1 | 2018 | 231 | 0.530 |
Why?
|
Anti-Anxiety Agents | 1 | 2015 | 23 | 0.530 |
Why?
|
Feeding and Eating Disorders | 4 | 2022 | 173 | 0.520 |
Why?
|
Parkinson Disease | 3 | 2014 | 132 | 0.520 |
Why?
|
Hoarding Disorder | 2 | 2015 | 7 | 0.520 |
Why?
|
Thinking | 1 | 2015 | 33 | 0.520 |
Why?
|
Spatial Memory | 1 | 2015 | 27 | 0.520 |
Why?
|
Thalamus | 1 | 2016 | 132 | 0.520 |
Why?
|
White Matter | 1 | 2016 | 80 | 0.510 |
Why?
|
Life Change Events | 1 | 2015 | 48 | 0.510 |
Why?
|
Marijuana Abuse | 1 | 2014 | 26 | 0.510 |
Why?
|
Endophenotypes | 1 | 2014 | 17 | 0.510 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 2357 | 0.500 |
Why?
|
Monoamine Oxidase Inhibitors | 3 | 2023 | 6 | 0.500 |
Why?
|
Expectorants | 1 | 2014 | 6 | 0.490 |
Why?
|
Placebos | 9 | 2013 | 218 | 0.480 |
Why?
|
Pain | 1 | 2016 | 391 | 0.480 |
Why?
|
Health Policy | 3 | 2021 | 180 | 0.480 |
Why?
|
Research Support as Topic | 1 | 2014 | 80 | 0.480 |
Why?
|
Dissociative Disorders | 2 | 2004 | 9 | 0.480 |
Why?
|
Skin Diseases | 1 | 2015 | 166 | 0.470 |
Why?
|
Organ Size | 3 | 2020 | 364 | 0.470 |
Why?
|
Pandemics | 5 | 2022 | 740 | 0.470 |
Why?
|
Neurobiology | 1 | 2013 | 10 | 0.460 |
Why?
|
Parents | 2 | 2021 | 272 | 0.460 |
Why?
|
Cross-Over Studies | 6 | 2021 | 399 | 0.450 |
Why?
|
Excitatory Amino Acid Agents | 2 | 2010 | 5 | 0.450 |
Why?
|
Brain Mapping | 2 | 2013 | 548 | 0.440 |
Why?
|
Dopamine | 6 | 2022 | 275 | 0.440 |
Why?
|
Nerve Fibers, Myelinated | 1 | 2012 | 31 | 0.440 |
Why?
|
Parenting | 3 | 2021 | 67 | 0.440 |
Why?
|
Catechol O-Methyltransferase Inhibitors | 2 | 2022 | 8 | 0.440 |
Why?
|
Citalopram | 2 | 2017 | 20 | 0.440 |
Why?
|
Mood Disorders | 5 | 2024 | 81 | 0.430 |
Why?
|
Psychomotor Performance | 6 | 2018 | 492 | 0.430 |
Why?
|
Antimanic Agents | 3 | 2007 | 11 | 0.430 |
Why?
|
Aggression | 4 | 2018 | 320 | 0.430 |
Why?
|
Parietal Lobe | 1 | 2013 | 117 | 0.430 |
Why?
|
Students, Medical | 1 | 2017 | 384 | 0.430 |
Why?
|
Psychiatry | 4 | 2019 | 78 | 0.430 |
Why?
|
Violence | 1 | 2014 | 143 | 0.430 |
Why?
|
Logistic Models | 4 | 2021 | 1187 | 0.430 |
Why?
|
Motivational Interviewing | 3 | 2021 | 18 | 0.420 |
Why?
|
Internal-External Control | 2 | 2009 | 44 | 0.420 |
Why?
|
Social Adjustment | 5 | 2015 | 46 | 0.420 |
Why?
|
Body Mass Index | 5 | 2016 | 770 | 0.410 |
Why?
|
Demography | 6 | 2020 | 177 | 0.410 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 449 | 0.410 |
Why?
|
Hair | 2 | 2022 | 56 | 0.410 |
Why?
|
Marijuana Smoking | 1 | 2011 | 29 | 0.410 |
Why?
|
Intention to Treat Analysis | 3 | 2021 | 72 | 0.400 |
Why?
|
Nerve Net | 2 | 2013 | 366 | 0.400 |
Why?
|
Cannabinoid Receptor Agonists | 1 | 2011 | 10 | 0.400 |
Why?
|
Rehabilitation, Vocational | 1 | 2011 | 4 | 0.400 |
Why?
|
Health Surveys | 5 | 2013 | 239 | 0.390 |
Why?
|
Problem Solving | 1 | 2011 | 54 | 0.390 |
Why?
|
Blood Pressure | 4 | 2019 | 1144 | 0.390 |
Why?
|
Antiparkinson Agents | 1 | 2010 | 15 | 0.390 |
Why?
|
Educational Status | 4 | 2022 | 188 | 0.380 |
Why?
|
Transsexualism | 1 | 2011 | 34 | 0.380 |
Why?
|
Research | 5 | 2022 | 253 | 0.360 |
Why?
|
Sex Characteristics | 1 | 2012 | 319 | 0.360 |
Why?
|
Child of Impaired Parents | 1 | 2009 | 19 | 0.360 |
Why?
|
Patient Selection | 1 | 2014 | 686 | 0.360 |
Why?
|
Bankruptcy | 1 | 2009 | 2 | 0.360 |
Why?
|
Calcium Channel Blockers | 1 | 2010 | 203 | 0.350 |
Why?
|
Disability Evaluation | 3 | 2016 | 136 | 0.350 |
Why?
|
Single-Blind Method | 5 | 2017 | 153 | 0.350 |
Why?
|
Character | 1 | 2009 | 6 | 0.350 |
Why?
|
Health Status | 4 | 2017 | 360 | 0.340 |
Why?
|
Glutamic Acid | 2 | 2022 | 152 | 0.340 |
Why?
|
Pica | 1 | 2008 | 14 | 0.330 |
Why?
|
Factor Analysis, Statistical | 4 | 2019 | 111 | 0.330 |
Why?
|
Cohort Studies | 5 | 2020 | 2767 | 0.330 |
Why?
|
Ambulatory Care | 5 | 2013 | 181 | 0.330 |
Why?
|
Internationality | 2 | 2018 | 69 | 0.320 |
Why?
|
Phenotype | 5 | 2023 | 2380 | 0.320 |
Why?
|
Time Factors | 7 | 2020 | 5210 | 0.320 |
Why?
|
Autonomic Nervous System | 2 | 2019 | 56 | 0.320 |
Why?
|
Brazil | 6 | 2018 | 69 | 0.310 |
Why?
|
Smoking Cessation | 3 | 2022 | 230 | 0.300 |
Why?
|
Motor Activity | 1 | 2009 | 327 | 0.300 |
Why?
|
Delusions | 2 | 2006 | 11 | 0.300 |
Why?
|
Glutamates | 2 | 2023 | 89 | 0.300 |
Why?
|
Lithium Carbonate | 1 | 2006 | 8 | 0.290 |
Why?
|
Anger | 2 | 2018 | 78 | 0.290 |
Why?
|
Drug Therapy, Combination | 4 | 2017 | 894 | 0.280 |
Why?
|
Touch | 1 | 2007 | 89 | 0.280 |
Why?
|
Heart Rate | 3 | 2019 | 492 | 0.280 |
Why?
|
Social Environment | 2 | 2011 | 188 | 0.280 |
Why?
|
Anisotropy | 4 | 2012 | 62 | 0.280 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 92 | 0.270 |
Why?
|
Electroconvulsive Therapy | 2 | 2007 | 24 | 0.270 |
Why?
|
Genetic Predisposition to Disease | 4 | 2019 | 2271 | 0.270 |
Why?
|
Illinois | 2 | 2017 | 462 | 0.270 |
Why?
|
Psychotherapy, Group | 2 | 2018 | 33 | 0.270 |
Why?
|
Ethanol | 2 | 2022 | 249 | 0.270 |
Why?
|
Endorphins | 2 | 2007 | 13 | 0.270 |
Why?
|
Hospitalization | 3 | 2007 | 849 | 0.270 |
Why?
|
Risk Assessment | 3 | 2021 | 2262 | 0.260 |
Why?
|
Mental Status Schedule | 2 | 2015 | 26 | 0.260 |
Why?
|
Linear Models | 3 | 2013 | 421 | 0.260 |
Why?
|
Object Attachment | 2 | 2021 | 20 | 0.260 |
Why?
|
Needs Assessment | 2 | 2018 | 154 | 0.260 |
Why?
|
Incidence | 3 | 2014 | 1577 | 0.260 |
Why?
|
Sex Distribution | 3 | 2011 | 173 | 0.250 |
Why?
|
Canada | 2 | 2017 | 204 | 0.250 |
Why?
|
Prognosis | 4 | 2015 | 3680 | 0.240 |
Why?
|
Terminology as Topic | 2 | 2015 | 217 | 0.240 |
Why?
|
Predictive Value of Tests | 3 | 2016 | 1673 | 0.240 |
Why?
|
Consumer Behavior | 1 | 2004 | 29 | 0.240 |
Why?
|
Diagnosis, Computer-Assisted | 2 | 2018 | 332 | 0.230 |
Why?
|
Pain Measurement | 2 | 2007 | 321 | 0.230 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2018 | 1204 | 0.230 |
Why?
|
Receptor, Adenosine A2A | 1 | 2023 | 15 | 0.230 |
Why?
|
Criminal Behavior | 1 | 2022 | 3 | 0.230 |
Why?
|
Free Radical Scavengers | 2 | 2013 | 59 | 0.220 |
Why?
|
Mass Screening | 2 | 2021 | 618 | 0.220 |
Why?
|
Retrospective Studies | 9 | 2022 | 8491 | 0.220 |
Why?
|
Aged, 80 and over | 6 | 2023 | 6509 | 0.220 |
Why?
|
Chronic Disease | 3 | 2014 | 971 | 0.220 |
Why?
|
Remission Induction | 2 | 2015 | 722 | 0.220 |
Why?
|
Waiting Lists | 1 | 2004 | 175 | 0.220 |
Why?
|
Drug Monitoring | 2 | 2013 | 118 | 0.220 |
Why?
|
Aripiprazole | 1 | 2022 | 5 | 0.210 |
Why?
|
Genotype | 4 | 2015 | 1851 | 0.210 |
Why?
|
Internal Capsule | 1 | 2021 | 4 | 0.210 |
Why?
|
Psychophysiologic Disorders | 1 | 2001 | 7 | 0.210 |
Why?
|
Psychiatric Department, Hospital | 1 | 2001 | 4 | 0.210 |
Why?
|
Autism Spectrum Disorder | 1 | 2023 | 76 | 0.210 |
Why?
|
Culture | 2 | 2015 | 53 | 0.210 |
Why?
|
Developing Countries | 2 | 2020 | 71 | 0.200 |
Why?
|
Psychomotor Agitation | 1 | 2001 | 26 | 0.200 |
Why?
|
Gray Matter | 1 | 2021 | 33 | 0.200 |
Why?
|
Pirenzepine | 1 | 2001 | 8 | 0.200 |
Why?
|
Tourette Syndrome | 2 | 2018 | 25 | 0.200 |
Why?
|
Parent-Child Relations | 1 | 2002 | 77 | 0.200 |
Why?
|
Dopamine Agonists | 2 | 2014 | 27 | 0.190 |
Why?
|
Fathers | 1 | 2021 | 70 | 0.190 |
Why?
|
Irritable Mood | 1 | 2020 | 10 | 0.190 |
Why?
|
Secondary Prevention | 2 | 2013 | 162 | 0.190 |
Why?
|
Outpatients | 3 | 2008 | 94 | 0.190 |
Why?
|
Schools | 2 | 2011 | 71 | 0.190 |
Why?
|
Delivery of Health Care | 3 | 2018 | 426 | 0.190 |
Why?
|
Regression Analysis | 3 | 2018 | 596 | 0.190 |
Why?
|
Safe Sex | 1 | 2020 | 23 | 0.190 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2007 | 865 | 0.190 |
Why?
|
Program Evaluation | 2 | 2013 | 297 | 0.180 |
Why?
|
Off-Label Use | 1 | 2020 | 16 | 0.180 |
Why?
|
Enzyme Inhibitors | 2 | 2013 | 639 | 0.180 |
Why?
|
Recreation | 2 | 2016 | 7 | 0.180 |
Why?
|
Phobic Disorders | 3 | 2013 | 13 | 0.180 |
Why?
|
Dementia | 1 | 2001 | 187 | 0.180 |
Why?
|
Principal Component Analysis | 2 | 2018 | 155 | 0.170 |
Why?
|
Neurosurgical Procedures | 1 | 2021 | 213 | 0.170 |
Why?
|
Unsafe Sex | 1 | 2019 | 42 | 0.170 |
Why?
|
Neoplasms | 1 | 2014 | 2898 | 0.170 |
Why?
|
Prescription Drug Diversion | 1 | 2018 | 1 | 0.170 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 429 | 0.170 |
Why?
|
Connecticut | 2 | 2011 | 27 | 0.170 |
Why?
|
Least-Squares Analysis | 1 | 2018 | 48 | 0.170 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2011 | 16 | 0.170 |
Why?
|
Brief Psychiatric Rating Scale | 1 | 2018 | 6 | 0.170 |
Why?
|
Bias | 2 | 2022 | 127 | 0.170 |
Why?
|
Drug Users | 1 | 2018 | 19 | 0.170 |
Why?
|
Feasibility Studies | 1 | 2021 | 751 | 0.170 |
Why?
|
Referral and Consultation | 1 | 2001 | 328 | 0.160 |
Why?
|
Social Media | 1 | 2020 | 79 | 0.160 |
Why?
|
Anger Management Therapy | 1 | 2018 | 1 | 0.160 |
Why?
|
Delphi Technique | 2 | 2018 | 80 | 0.160 |
Why?
|
Chi-Square Distribution | 2 | 2009 | 364 | 0.160 |
Why?
|
Practice Guidelines as Topic | 2 | 2016 | 1036 | 0.160 |
Why?
|
Gonadal Steroid Hormones | 1 | 2018 | 50 | 0.160 |
Why?
|
Forensic Psychiatry | 1 | 2017 | 5 | 0.160 |
Why?
|
Public Opinion | 1 | 2017 | 43 | 0.160 |
Why?
|
Smoking Prevention | 2 | 2014 | 43 | 0.150 |
Why?
|
Basal Ganglia | 1 | 2017 | 42 | 0.150 |
Why?
|
Employment | 2 | 2007 | 52 | 0.150 |
Why?
|
Clomipramine | 1 | 2017 | 3 | 0.150 |
Why?
|
Mental Health Services | 2 | 2018 | 48 | 0.150 |
Why?
|
Geriatric Psychiatry | 1 | 2017 | 18 | 0.150 |
Why?
|
Neurotransmitter Agents | 2 | 2008 | 106 | 0.150 |
Why?
|
Homosexuality, Male | 2 | 2014 | 298 | 0.150 |
Why?
|
Haplotypes | 1 | 2019 | 642 | 0.150 |
Why?
|
Panic Disorder | 1 | 2016 | 22 | 0.150 |
Why?
|
Online Systems | 1 | 2016 | 24 | 0.140 |
Why?
|
Affect | 2 | 2011 | 386 | 0.140 |
Why?
|
Tertiary Care Centers | 1 | 2016 | 94 | 0.140 |
Why?
|
Cognitive Remediation | 1 | 2015 | 1 | 0.140 |
Why?
|
Therapies, Investigational | 1 | 2015 | 17 | 0.140 |
Why?
|
Focus Groups | 1 | 2016 | 155 | 0.140 |
Why?
|
Standard of Care | 1 | 2016 | 79 | 0.140 |
Why?
|
Societies, Medical | 2 | 2016 | 572 | 0.140 |
Why?
|
Hydrocortisone | 3 | 2007 | 298 | 0.130 |
Why?
|
Heuristics | 1 | 2015 | 15 | 0.130 |
Why?
|
Family Characteristics | 2 | 2008 | 48 | 0.130 |
Why?
|
Interpersonal Relations | 2 | 2014 | 170 | 0.130 |
Why?
|
Feedback, Psychological | 1 | 2015 | 18 | 0.130 |
Why?
|
Nervous System | 1 | 2015 | 86 | 0.130 |
Why?
|
Learning | 2 | 2018 | 280 | 0.130 |
Why?
|
Achievement | 1 | 2015 | 29 | 0.130 |
Why?
|
Animals | 6 | 2015 | 26589 | 0.130 |
Why?
|
Drinking Behavior | 1 | 2014 | 13 | 0.130 |
Why?
|
Body Weight | 2 | 2015 | 459 | 0.130 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2014 | 19 | 0.130 |
Why?
|
Health Resources | 1 | 2015 | 76 | 0.130 |
Why?
|
Perception | 1 | 2015 | 168 | 0.130 |
Why?
|
Discriminant Analysis | 1 | 2014 | 66 | 0.120 |
Why?
|
Disease Models, Animal | 3 | 2013 | 2232 | 0.120 |
Why?
|
Public Sector | 1 | 2014 | 12 | 0.120 |
Why?
|
Foundations | 1 | 2014 | 25 | 0.120 |
Why?
|
Weight Loss | 2 | 2015 | 229 | 0.120 |
Why?
|
Task Performance and Analysis | 1 | 2014 | 86 | 0.120 |
Why?
|
Patient Dropouts | 1 | 2014 | 28 | 0.120 |
Why?
|
Technology | 1 | 2014 | 29 | 0.120 |
Why?
|
Public Policy | 1 | 2014 | 52 | 0.120 |
Why?
|
Science | 1 | 2014 | 34 | 0.120 |
Why?
|
Recurrence | 2 | 2008 | 1139 | 0.120 |
Why?
|
ROC Curve | 1 | 2016 | 752 | 0.120 |
Why?
|
Risk | 1 | 2015 | 674 | 0.120 |
Why?
|
Dangerous Behavior | 1 | 2013 | 4 | 0.120 |
Why?
|
Imagination | 1 | 2014 | 41 | 0.120 |
Why?
|
Pattern Recognition, Visual | 2 | 2012 | 151 | 0.120 |
Why?
|
Costs and Cost Analysis | 1 | 2014 | 153 | 0.120 |
Why?
|
Community Mental Health Centers | 1 | 2013 | 3 | 0.120 |
Why?
|
Models, Statistical | 1 | 2017 | 575 | 0.120 |
Why?
|
Observer Variation | 2 | 2006 | 602 | 0.120 |
Why?
|
Probability | 1 | 2014 | 355 | 0.120 |
Why?
|
Cognitive Dissonance | 1 | 2013 | 3 | 0.120 |
Why?
|
Drug Therapy | 2 | 2006 | 70 | 0.120 |
Why?
|
Sample Size | 1 | 2014 | 130 | 0.120 |
Why?
|
Attitude to Computers | 1 | 2013 | 12 | 0.120 |
Why?
|
Stroop Test | 1 | 2013 | 9 | 0.120 |
Why?
|
Feeding Behavior | 2 | 2015 | 324 | 0.110 |
Why?
|
Lost to Follow-Up | 1 | 2013 | 12 | 0.110 |
Why?
|
Diagnostic Errors | 1 | 2014 | 160 | 0.110 |
Why?
|
Odds Ratio | 2 | 2012 | 678 | 0.110 |
Why?
|
Isoxazoles | 1 | 2013 | 77 | 0.110 |
Why?
|
Europe | 3 | 2018 | 309 | 0.110 |
Why?
|
Biomarkers | 2 | 2018 | 1718 | 0.110 |
Why?
|
Bibliometrics | 1 | 2013 | 37 | 0.110 |
Why?
|
International Cooperation | 1 | 2013 | 127 | 0.110 |
Why?
|
Reversal Learning | 1 | 2012 | 15 | 0.110 |
Why?
|
Cicatrix | 1 | 2012 | 63 | 0.110 |
Why?
|
Denmark | 1 | 2012 | 15 | 0.110 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2012 | 100 | 0.100 |
Why?
|
Affective Symptoms | 1 | 2012 | 47 | 0.100 |
Why?
|
Systems Analysis | 1 | 2011 | 17 | 0.100 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 130 | 0.100 |
Why?
|
Activities of Daily Living | 2 | 2010 | 204 | 0.100 |
Why?
|
Diet | 1 | 2015 | 443 | 0.100 |
Why?
|
Orientation | 1 | 2012 | 119 | 0.100 |
Why?
|
Hospitals, University | 2 | 2002 | 194 | 0.100 |
Why?
|
Health Behavior | 1 | 2013 | 183 | 0.100 |
Why?
|
Cooperative Behavior | 1 | 2012 | 174 | 0.100 |
Why?
|
Family Therapy | 1 | 2011 | 16 | 0.100 |
Why?
|
Australia | 2 | 2023 | 99 | 0.100 |
Why?
|
Income | 2 | 2018 | 75 | 0.100 |
Why?
|
Patient Compliance | 1 | 2012 | 227 | 0.100 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 579 | 0.100 |
Why?
|
Causality | 1 | 2011 | 81 | 0.100 |
Why?
|
Age Distribution | 1 | 2011 | 204 | 0.090 |
Why?
|
Benzhydryl Compounds | 1 | 2010 | 48 | 0.090 |
Why?
|
Pyrimidines | 1 | 2013 | 370 | 0.090 |
Why?
|
Primary Health Care | 1 | 2013 | 339 | 0.090 |
Why?
|
Self-Help Groups | 1 | 2009 | 14 | 0.090 |
Why?
|
Marital Status | 1 | 2009 | 40 | 0.090 |
Why?
|
Republic of Korea | 1 | 2009 | 31 | 0.090 |
Why?
|
Grooming | 1 | 2009 | 17 | 0.090 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 307 | 0.090 |
Why?
|
Harm Reduction | 1 | 2009 | 16 | 0.090 |
Why?
|
Propylamines | 1 | 2008 | 9 | 0.090 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2008 | 9 | 0.090 |
Why?
|
Healthy Volunteers | 2 | 2023 | 143 | 0.090 |
Why?
|
Data Interpretation, Statistical | 2 | 2010 | 297 | 0.080 |
Why?
|
Alcoholic Intoxication | 1 | 2009 | 31 | 0.080 |
Why?
|
Neural Inhibition | 1 | 2009 | 97 | 0.080 |
Why?
|
Research Design | 1 | 2011 | 594 | 0.080 |
Why?
|
Hygiene | 1 | 2007 | 10 | 0.080 |
Why?
|
Mentally Ill Persons | 1 | 2007 | 5 | 0.080 |
Why?
|
Poverty | 2 | 2020 | 173 | 0.080 |
Why?
|
Amygdala | 1 | 2008 | 84 | 0.080 |
Why?
|
Nicotine | 1 | 2009 | 194 | 0.080 |
Why?
|
Attitude to Health | 1 | 2009 | 220 | 0.080 |
Why?
|
North America | 2 | 2018 | 180 | 0.070 |
Why?
|
Receptors, Neurotransmitter | 1 | 2006 | 25 | 0.070 |
Why?
|
Amnesia | 1 | 2007 | 14 | 0.070 |
Why?
|
Inpatients | 1 | 2010 | 297 | 0.070 |
Why?
|
Cluster Analysis | 2 | 2023 | 369 | 0.070 |
Why?
|
Epinephrine | 1 | 2006 | 84 | 0.070 |
Why?
|
Awareness | 1 | 2007 | 93 | 0.070 |
Why?
|
Fructose | 1 | 2006 | 35 | 0.070 |
Why?
|
Bulimia | 1 | 2007 | 140 | 0.070 |
Why?
|
Transaminases | 1 | 2006 | 34 | 0.070 |
Why?
|
Social Control, Formal | 1 | 2005 | 12 | 0.070 |
Why?
|
Arousal | 1 | 2006 | 170 | 0.070 |
Why?
|
Algorithms | 3 | 2014 | 1830 | 0.070 |
Why?
|
Lifting | 2 | 1995 | 12 | 0.070 |
Why?
|
Mesencephalon | 1 | 2006 | 64 | 0.070 |
Why?
|
Religion | 1 | 2006 | 87 | 0.070 |
Why?
|
Neuroprotective Agents | 1 | 2006 | 94 | 0.070 |
Why?
|
Space Perception | 1 | 2007 | 115 | 0.070 |
Why?
|
Receptors, Dopamine | 1 | 2005 | 38 | 0.070 |
Why?
|
Risperidone | 1 | 2005 | 23 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2009 | 469 | 0.060 |
Why?
|
Prefrontal Cortex | 1 | 2006 | 129 | 0.060 |
Why?
|
beta-Endorphin | 1 | 2004 | 11 | 0.060 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2007 | 294 | 0.060 |
Why?
|
London | 1 | 2004 | 16 | 0.060 |
Why?
|
State Medicine | 1 | 2004 | 12 | 0.060 |
Why?
|
Models, Econometric | 1 | 2004 | 14 | 0.060 |
Why?
|
Adaptation, Psychological | 1 | 2005 | 157 | 0.060 |
Why?
|
Prolactin | 1 | 2004 | 88 | 0.060 |
Why?
|
Hemolysin Proteins | 1 | 2004 | 34 | 0.060 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2004 | 131 | 0.060 |
Why?
|
Streptococcal Infections | 1 | 2004 | 57 | 0.060 |
Why?
|
Visual Perception | 1 | 2007 | 319 | 0.060 |
Why?
|
Hot Temperature | 1 | 2004 | 206 | 0.060 |
Why?
|
Adenosine A2 Receptor Antagonists | 1 | 2023 | 13 | 0.060 |
Why?
|
Policy | 1 | 2023 | 34 | 0.060 |
Why?
|
Patient Satisfaction | 2 | 2004 | 455 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2005 | 329 | 0.060 |
Why?
|
Hospitals, Psychiatric | 1 | 2002 | 22 | 0.060 |
Why?
|
Ambulatory Care Facilities | 1 | 2004 | 102 | 0.060 |
Why?
|
Guilt | 1 | 2002 | 11 | 0.050 |
Why?
|
Psychopathology | 1 | 2002 | 29 | 0.050 |
Why?
|
Reference Values | 1 | 2004 | 674 | 0.050 |
Why?
|
Varenicline | 1 | 2022 | 13 | 0.050 |
Why?
|
Communicable Disease Control | 1 | 2022 | 51 | 0.050 |
Why?
|
Exploratory Behavior | 1 | 2002 | 44 | 0.050 |
Why?
|
Social Perception | 1 | 2003 | 95 | 0.050 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2007 | 663 | 0.050 |
Why?
|
Smokers | 1 | 2022 | 41 | 0.050 |
Why?
|
Utilization Review | 1 | 2001 | 21 | 0.050 |
Why?
|
Psychological Theory | 1 | 2021 | 22 | 0.050 |
Why?
|
Boredom | 1 | 2001 | 1 | 0.050 |
Why?
|
Behavior | 1 | 2021 | 85 | 0.050 |
Why?
|
Italy | 1 | 2021 | 106 | 0.050 |
Why?
|
Benzodiazepines | 1 | 2001 | 65 | 0.050 |
Why?
|
Liver | 1 | 2006 | 1230 | 0.050 |
Why?
|
Counseling | 1 | 2022 | 145 | 0.050 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 2000 | 26 | 0.050 |
Why?
|
Russia | 1 | 2020 | 25 | 0.050 |
Why?
|
Attentional Bias | 1 | 2020 | 8 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2022 | 361 | 0.050 |
Why?
|
Forecasting | 1 | 2001 | 304 | 0.050 |
Why?
|
England | 1 | 2019 | 41 | 0.050 |
Why?
|
Help-Seeking Behavior | 1 | 2019 | 1 | 0.040 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 243 | 0.040 |
Why?
|
Medical History Taking | 1 | 2019 | 80 | 0.040 |
Why?
|
Gastric Bypass | 1 | 2000 | 110 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2020 | 319 | 0.040 |
Why?
|
National Institute of Mental Health (U.S.) | 1 | 2018 | 22 | 0.040 |
Why?
|
South America | 1 | 2018 | 29 | 0.040 |
Why?
|
Asia | 1 | 2018 | 95 | 0.040 |
Why?
|
Preliminary Data | 1 | 2018 | 1 | 0.040 |
Why?
|
Controlled Before-After Studies | 1 | 2018 | 3 | 0.040 |
Why?
|
Obesity, Morbid | 1 | 2000 | 225 | 0.040 |
Why?
|
Exercise | 1 | 2020 | 315 | 0.040 |
Why?
|
Libya | 1 | 2016 | 3 | 0.040 |
Why?
|
Israel | 1 | 2016 | 55 | 0.040 |
Why?
|
Child, Preschool | 2 | 2015 | 3613 | 0.040 |
Why?
|
Liver Function Tests | 2 | 2010 | 93 | 0.040 |
Why?
|
Hypochondriasis | 1 | 2015 | 1 | 0.030 |
Why?
|
Intervertebral Disc Displacement | 1 | 1995 | 24 | 0.030 |
Why?
|
Mice | 1 | 2009 | 11356 | 0.030 |
Why?
|
Low Back Pain | 1 | 1995 | 40 | 0.030 |
Why?
|
Alcohol Abstinence | 1 | 2014 | 7 | 0.030 |
Why?
|
Lumbar Vertebrae | 1 | 1995 | 148 | 0.030 |
Why?
|
Government | 1 | 2014 | 9 | 0.030 |
Why?
|
Disabled Persons | 1 | 1995 | 67 | 0.030 |
Why?
|
Private Sector | 1 | 2014 | 19 | 0.030 |
Why?
|
Inventions | 1 | 2014 | 13 | 0.030 |
Why?
|
Politics | 1 | 2014 | 50 | 0.030 |
Why?
|
Life Expectancy | 1 | 2014 | 86 | 0.030 |
Why?
|
Climate Change | 1 | 2014 | 42 | 0.030 |
Why?
|
Resource Allocation | 1 | 2014 | 65 | 0.030 |
Why?
|
Paliperidone Palmitate | 1 | 2013 | 2 | 0.030 |
Why?
|
Population Dynamics | 1 | 2014 | 130 | 0.030 |
Why?
|
Conservation of Natural Resources | 1 | 2014 | 79 | 0.030 |
Why?
|
Environment | 1 | 2014 | 219 | 0.030 |
Why?
|
Knowledge Management | 1 | 2011 | 3 | 0.030 |
Why?
|
Knowledge Bases | 1 | 2011 | 14 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2012 | 229 | 0.030 |
Why?
|
Family Health | 1 | 2012 | 162 | 0.030 |
Why?
|
Drug Interactions | 2 | 2002 | 248 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2013 | 373 | 0.020 |
Why?
|
Genetic Linkage | 1 | 2012 | 623 | 0.020 |
Why?
|
Atrophy | 1 | 2010 | 117 | 0.020 |
Why?
|
Computer Simulation | 1 | 2014 | 1078 | 0.020 |
Why?
|
Temporal Lobe | 1 | 2010 | 172 | 0.020 |
Why?
|
Atomoxetine Hydrochloride | 1 | 2008 | 5 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2012 | 1074 | 0.020 |
Why?
|
Self Efficacy | 1 | 2009 | 53 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2011 | 482 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2013 | 1924 | 0.020 |
Why?
|
Motor Cortex | 1 | 2010 | 195 | 0.020 |
Why?
|
Psychotic Disorders | 1 | 2010 | 184 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2008 | 62 | 0.020 |
Why?
|
Catecholamines | 1 | 2007 | 88 | 0.020 |
Why?
|
Norepinephrine | 1 | 2007 | 167 | 0.020 |
Why?
|
Dominance, Cerebral | 1 | 2007 | 66 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2006 | 73 | 0.020 |
Why?
|
Aspartate Aminotransferases | 1 | 2006 | 73 | 0.020 |
Why?
|
Work Capacity Evaluation | 2 | 1995 | 4 | 0.020 |
Why?
|
Fluvoxamine | 1 | 2005 | 6 | 0.020 |
Why?
|
Valproic Acid | 1 | 2005 | 24 | 0.020 |
Why?
|
Lithium | 1 | 2005 | 59 | 0.020 |
Why?
|
Prospective Studies | 2 | 2005 | 4213 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 1621 | 0.020 |
Why?
|
Antistreptolysin | 1 | 2004 | 1 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2004 | 151 | 0.010 |
Why?
|
Electroencephalography | 1 | 2007 | 709 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 2004 | 241 | 0.010 |
Why?
|
Postoperative Nausea and Vomiting | 1 | 2000 | 17 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 2000 | 274 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2005 | 1991 | 0.010 |
Why?
|
Safety | 1 | 2000 | 152 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 2000 | 306 | 0.010 |
Why?
|
Bacterial Proteins | 1 | 2004 | 864 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2004 | 1376 | 0.010 |
Why?
|
Survival Rate | 1 | 2000 | 1863 | 0.010 |
Why?
|
Back Injuries | 1 | 1995 | 6 | 0.010 |
Why?
|
Body Constitution | 1 | 1995 | 26 | 0.010 |
Why?
|
Ergonomics | 1 | 1995 | 21 | 0.010 |
Why?
|
Biomechanical Phenomena | 1 | 1995 | 457 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2000 | 2207 | 0.010 |
Why?
|